⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AARD News
Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman
globenewswire.com
AARD
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman
prnewswire.com
AARD
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman
globenewswire.com
AARD
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman
prnewswire.com
AARD
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman
globenewswire.com
AARD
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out
accessnewswire.com
AARD
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Shareholders to Learn More About the Investigation
accessnewswire.com
AARD
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
accessnewswire.com
AARD
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire about Securities Investigation
accessnewswire.com
AARD
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Investors to Connect
accessnewswire.com
AARD